دورية أكاديمية
أعرض في EDS

Effect of MDR1 C3435T and CYP2C19 genetic polymorphisms on the outcome of Helicobacter pylori eradication treatment in children with gastritis and peptic ulcer, Vietnam.

التفاصيل البيبلوغرافية
العنوان: Effect of MDR1 C3435T and CYP2C19 genetic polymorphisms on the outcome of Helicobacter pylori eradication treatment in children with gastritis and peptic ulcer, Vietnam.
المؤلفون: Thuy LLT; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.; Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam., Nguyen LT; Faculty of Nursing and Medical Technology, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam., Vu HA; Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam., Nguyen NA; Department of Pediatrics, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. nghianguyen@ump.edu.vn., Nguyen TA; Department of Pediatrics, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. nguyenanhtuan@ump.edu.vn.
المصدر: BMC pediatrics [BMC Pediatr] 2024 Jul 19; Vol. 24 (1), pp. 464. Date of Electronic Publication: 2024 Jul 19.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967804 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2431 (Electronic) Linking ISSN: 14712431 NLM ISO Abbreviation: BMC Pediatr Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Cytochrome P-450 CYP2C19*/genetics , Helicobacter Infections*/drug therapy , Helicobacter Infections*/genetics , Helicobacter pylori*/drug effects , Gastritis*/drug therapy , Gastritis*/microbiology , Gastritis*/genetics , Peptic Ulcer*/drug therapy , Peptic Ulcer*/genetics , Peptic Ulcer*/microbiology , ATP Binding Cassette Transporter, Subfamily B*/genetics , Proton Pump Inhibitors*/therapeutic use, Humans ; Child ; Male ; Female ; Vietnam ; Adolescent ; Child, Preschool ; Genotype ; Polymorphism, Genetic ; Treatment Outcome ; Esomeprazole/therapeutic use ; Anti-Bacterial Agents/therapeutic use
مستخلص: Background: Helicobacter pylori eradication therapy based on antimicrobial susceptibility in Vietnamese children currently get low efficiency. There are causes of treatment failure, among host genetic factors namely MDR1 C3435T and CYP2C19 affect the absorption and metabolism of proton pump inhibitors - a crucial component of eradication therapy. The study aimed to investigate the effect of MDR1 C3435T and CYP2C19 genetic polymorphisms on the cure rate.
Methods: 207 pediatric patients with gastritis and peptic ulcer infecting Helicobacter pylori completed the eradication therapy based on antimicrobial susceptibility with proton pump inhibitor esomeprazole. Eradication efficacy was assessed after at least 4 weeks by the urease breath test. MDR1 C3435T genetic polymorphism and CYP2C19 genotype were determined using a sequencing method based on Sanger's principle.
Results: Among 207 children recruited in this study, the ratio of CYP2C19 EM, IM, and PM phenotypes was 40.1%, 46.4%, and 16.9%, respectively. The patient with MDR1 3435 C/C polymorphism accounted for 43.0%, MDR1 3435 C/T was 40.1%, and MDR1 3435T/T was 16.9%. The cure rate of Helicobacter pylori infection in patients with CYP2C19 EM genotype was 78.3%; 83.3% of those with the IM genotype, and PM genotype was 96,4% (p = 0.07). Successful eradication rates for Helicobacter pylori were 85.4%, 86.7%, and 68.6% in patients with the MDR1 3435 C/C, C/T, and T/T, respectively (p = 0.02). Multiple logistic regression analysis found that MDR1 C3435T genetic polymorphisms of patients were significant independent risk factors for treatment failure, and CYP2C19 genotype did not affect Helicobacter pylori eradication.
Conclusions: The Helicobacter pylori eradication rates by regimens based on antibiotic susceptibility and esomeprazole were not significantly different between the CYP2C19 phenotypes. The MDR1 C3435T polymorphism is one of the factors impacting Helicobacter pylori eradication results in children.
(© 2024. The Author(s).)
References: Indian J Gastroenterol. 2014 Jul;33(4):330-5. (PMID: 24610583)
Zhonghua Er Ke Za Zhi. 2020 Jan 2;58(1):41-45. (PMID: 31905475)
Eur J Clin Pharmacol. 2009 Jun;65(6):593-600. (PMID: 19238367)
Clin Pharmacol Ther. 2021 Jun;109(6):1417-1423. (PMID: 32770672)
Helicobacter. 2010 Aug;15(4):265-72. (PMID: 20633187)
J Clin Biochem Nutr. 2016 Sep;59(2):149-153. (PMID: 27698544)
Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):405-16. (PMID: 20646336)
Helicobacter. 2008 Feb;13(1):69-74. (PMID: 18205669)
J Gastroenterol Hepatol. 2009 Feb;24(2):294-8. (PMID: 18823430)
J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):991-1003. (PMID: 28541262)
Genes (Basel). 2020 Jan 05;11(1):. (PMID: 31948121)
Medicine (Baltimore). 2017 Feb;96(7):e5859. (PMID: 28207505)
Eur J Clin Pharmacol. 2010 Jul;66(7):681-7. (PMID: 20376628)
Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):879-85. (PMID: 27010145)
Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1243-1247. (PMID: 31030500)
Ann Hum Biol. 2019 Sep;46(6):491-497. (PMID: 31766957)
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8. (PMID: 10716719)
Basic Clin Pharmacol Toxicol. 2017 Feb;120(2):199-206. (PMID: 27611887)
Medicine (Baltimore). 2017 Mar;96(13):e6489. (PMID: 28353592)
Gastroenterology. 2021 Apr;160(5):1831-1841. (PMID: 33524402)
Dig Dis Sci. 2011 Jan;56(1):103-8. (PMID: 20464493)
Aliment Pharmacol Ther. 2007 Sep 1;26(5):693-703. (PMID: 17697203)
Pharmacol Rep. 2011;63(4):992-8. (PMID: 22001987)
Pediatrics. 2019 Dec;144(6):. (PMID: 31699831)
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460. (PMID: 29620484)
Pediatr Int. 2020 Dec;62(12):1315-1331. (PMID: 32657507)
Am J Surg Pathol. 1996 Oct;20(10):1161-81. (PMID: 8827022)
J Dig Dis. 2012 Aug;13(8):414-20. (PMID: 22788927)
World J Gastroenterol. 2015 Dec 28;21(48):13548-54. (PMID: 26730167)
فهرسة مساهمة: Keywords: CYP2C19; Children; Helicobacter pylori; MDR1 C3435T
المشرفين على المادة: EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
EC 1.14.14.1 (CYP2C19 protein, human)
0 (ATP Binding Cassette Transporter, Subfamily B)
0 (Proton Pump Inhibitors)
0 (ABCB1 protein, human)
N3PA6559FT (Esomeprazole)
0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20240719 Date Completed: 20240719 Latest Revision: 20240725
رمز التحديث: 20240726
مُعرف محوري في PubMed: PMC11264771
DOI: 10.1186/s12887-024-04581-w
PMID: 39030549
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2431
DOI:10.1186/s12887-024-04581-w